Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment

Paolo Vercellini, Nicoletta Vendola, Alberto Colombo, Cristina Passadore, Laura Trespidi, Pier Giorgio Crosignani

Research output: Contribution to journalArticlepeer-review


Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.

Original languageEnglish
Pages (from-to)102-104
Number of pages3
JournalGynecologic and Obstetric Investigation
Issue number2
Publication statusPublished - 1992


  • Antidopaminergic drugs
  • Gonadotropin-releasing hormone agonists
  • Hot flushes
  • Veralipride

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine


Dive into the research topics of 'Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment'. Together they form a unique fingerprint.

Cite this